OncLive® On Air

OncLive® On Air

By OncLive® On AirScienceHealth & Fitness
Download on the App Store
  • Favorites

    22

    Followers

  • Typical duration

    18 min

    per episode

Based on Podcast App listening data

OncLive® On Air episodes

  • S19 Ep21: Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management

    Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

    In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of localized prostate cancer diagnosis and management for 2026, reflecting the rapidly changing landscape of staging, systemic therapy, and perioperative treatment.

    The discussion began with disease presentation and risk assessment, noting that most cases are screen detected by elevated prostate-specific antigen levels and that prostate MRI is increasingly performed before biopsy. Drs Armstrong and Tawagi reviewed risk factors, such as older age, family history, Black African ancestry, and BRCA2 variants. They also explained the TNM staging system, Gleason grading, and National Comprehensive Cancer Network risk stratification. They emphasized that node-positive disease is stage IV in prostate cancer. They also highlighted the expanded role of prostate-specific membrane antigen PET imaging, particularly for high-risk and very high–risk disease, as well as the use of genomic classifiers.

    Regarding treatment, they described observation for patients with limited life expectancy, active surveillance, radiation, brachytherapy, and prostatectomy for low-risk disease, as well as radiation with 2 to 3 years of androgen deprivation therapy for high-risk disease. They noted that patients with very high–risk disease should also receive 2 years of abiraterone acetate (Zytiga) plus prednisone. They compared LHRH agonists, which require bicalutamide (Casodex) to prevent testosterone flare, with the antagonists degarelix (Firmagon) and relugolix (Orgovyx). Additionally, they reviewed androgen deprivation therapy (ADT)–associated toxicities and bone health management. Drs Armstrong and Tawagi also addressed biochemical recurrence and salvage radiation, and they concluded by highlighting recent data readouts.

    20 min
  • S19 Ep20: ESMO 2026 Data Continue to Shine a Spotlight on Daraxonrasib’s Activity in Pretreated Metastatic Pancreatic Cancer

    In today's episode, we spoke with Zev A. Wainberg, MD, MSc, about subgroup data from the phase 3 RASolute 302 trial (NCT06625320) of daraxonrasib (Rasonque) in patients with previously treated metastatic pancreatic cancer, which were presented at the 2026 ESMO Congress. Dr Wainberg is a professor of medicine at the David Geffen School of Medicine at UCLA and co-director of the UCLA GI Oncology Program in Los Angeles, California.

    In our exclusive interview, Dr Wainberg discussed how daraxonrasib improved overall survival (OS) vs investigator’s choice of standard-of-care chemotherapy across RAS genotype subgroups, preselected chemotherapy regimens, and prior treatment settings. Additionally, Dr Wainberg shared practical advice for managing rash and stomatitis, including treatment holds and dose reductions. Finally, Dr Wainberg explained how RAS(ON) inhibition is moving into earlier lines of therapy and why he supports genomic testing at diagnosis.

    Dr Wainberg presented the analyses at the 2026 ESMO Congress on behalf of the RASolute 302 investigators. The trial randomly assigned 500 patients with metastatic pancreatic adenocarcinoma who had received 1 prior fluoropyrimidine- or gemcitabine-based regimen in the metastatic setting to daraxonrasib at 300 mg once daily (n = 248) or investigator’s choice of chemotherapy (n = 252). In the primary analysis, daraxonrasib generated a median OS of 13.2 months (95% CI, 10.0-not estimable) vs 6.7 months (95% CI, 5.8-8.0) with chemotherapy (HR, 0.40; 95% CI, 0.30-0.53; P = 4.6 × 10–11).

    Dr Wainberg first addressed the subgroup findings by RAS genotype. RAS G12D and G12V mutations predominated, accounting for 43.2% and 35.6% of the study population, respectively, and Dr Wainberg noted that nearly every genotype subgroup favored daraxonrasib for OS. The OS HRs were 0.49 (95% CI, 0.33-0.74) in the G12D subgroup (n = 95 vs 121), 0.32 (95% CI, 0.19-0.54) in the G12V subgroup (n = 102 vs 76), 0.61 (95% CI, 0.29-1.30) in the G12R subgroup (n = 30 vs 31), and 0.43 (95% CI, 0.09-1.98) in patients with no RAS mutation identified (n = 9 vs 7). 

    Turning to sequencing, Dr Wainberg explained that neither the first-line regimen nor the chemotherapy selected for the control arm appeared to change the benefit of daraxonrasib. The OS HR was 0.45 (95% CI, 0.32-0.65) when gemcitabine plus nab-paclitaxel (Abraxane) was the preselected comparator (n = 140 vs 141), 0.46 (95% CI, 0.23-0.95) for pooled modified FOLFIRINOX or FOLFOX (n = 30 vs 30), and 0.32 (95% CI, 0.18-0.58) for nanoliposomal irinotecan (Onivyde) plus 5-fluorouracil and leucovorin (n = 78 vs 81).

    Looking ahead, Dr Wainberg noted that trials of RAS(ON) inhibition are already enrolling in the adjuvant and first-line settings, and that many KRAS inhibitors presented at the meeting are moving quickly to phase 3 studies.

    10 min
  • S19 Ep19: RAS Inhibition With Daraxonrasib Marks a Turning Point in Pancreatic Cancer Management

    In this episode of Oncology Unplugged, host Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by John L. Marshall, MD, the chief of hematology and oncology, a professor of medicine and oncology, and the director of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

    Their discussion centered on the evolution of pancreatic adenocarcinoma management over the past several decades, culminating in the emergence of RAS-directed therapy. Drs Park and Marshall traced the treatment history from early regimens, such as fluorouracil/doxorubicin/mitomycin and single-agent fluorouracil, to the approval of gemcitabine based on clinical benefit, followed by years of gemcitabine-combination trials in which only capecitabine and nab-paclitaxel (Abraxane) produced positive results, and finally to FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin).

    Dr Marshall explained RAS biology, emphasizing that since most pancreatic cancers harbor RAS mutations, severing this pathway can produce meaningful clinical benefit with a single agent, unlike in colorectal cancer. The experts reviewed data from the phase 3 RASolute 302 trial (NCT06625320) of the pan-RAS inhibitor daraxonrasib (Rasonque) presented at the 2026 ASCO Annual Meeting, in which second-line therapy yielded a median overall survival improvement vs chemotherapy. Dr Marshall tempered enthusiasm for these efficacy data by noting that response rates remained below 50% and that rash, affecting approximately 80% of patients, requires proactive prophylaxis, close follow-up, and dermatology collaboration. He cautioned against offering the agent to patients with poor performance status and discussed dose-optimization strategies.

    Drs Park and Marshall also highlighted the importance of moving RAS inhibition into earlier lines of therapy, as only approximately 10% of patients are surgical candidates, as well as the need for comprehensive genomic testing, including germline BRCA1/2 testing to identify eligible candidates for treatment with olaparib (Lynparza). The conversation concluded with the potential role of artificial intelligence in predicting treatment benefit.

    24 min
  • S19 Ep18: Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD

    In today’s episode, we welcomed Noa Biran, MD, to discuss some of the key multiple myeloma data to emerge from the 2026 ASCO Annual Meeting. Dr Biran is the medical director of Clinical Protocol Data Management and an associate professor of medicine in the Multiple Myeloma Division at Hackensack Meridian Health and John Theurer Cancer Center in New Jersey.

    In the exclusive interview, Dr Biran detailed key data from pivotal studies such as the phase 3 MajesTEC-9 (NCT05572515) and SUCCESSOR-2 (NCT05552976) trials, and explained how emerging data could affect the multiple myeloma treatment landscape.

    18 min
  • S19 Ep17: Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026

    In this episode of Oncology Unplugged, host Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Petros Grivas, MD, PhD, FASCO, the medical director of local/regional outreach and international program and a professor in the Clinical Research Division at Fred Hutch Cancer Center, as well as a professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle.

    Their discussion centered on key bladder cancer data presented at the 2026 ESMO Congress, highlighting the rapidly expanding landscape of perioperative, metastatic, and non–muscle-invasive disease management. Drs Park and Grivas first addressed findings from the phase 3 VOLGA trial (NCT04960709), which evaluated neoadjuvant durvalumab (Imfinzi) plus enfortumab vedotin-ejfv (Padcev), with or without tremelimumab (Imjudo), followed by cystectomy and adjuvant durvalumab in patients with cisplatin-ineligible or cisplatin-declining muscle-invasive bladder cancer. Dr Grivas noted that the durvalumab/enfortumab vedotin arm met both event-free survival (EFS) and overall survival (OS) end points, whereas the tremelimumab arm met the end point for EFS but not OS. He emphasized that the need for adjuvant enfortumab vedotin remains an open question.

    The conversation then turned to the discordant results among trials in cisplatin-eligible patients. Dr Grivas contrasted the positive phase 3 NIAGARA trial (NCT03732677) data with the results of the phase 3 KEYNOTE-866 (NCT03924856) and ENERGIZE (NCT03661320) trials, which did not meet their EFS end points, and noted that all 3 enfortumab vedotin–based perioperative trials were positive. They also discussed exploratory circulating tumor DNA analyses from VOLGA and the phase 3 KEYNOTE-B15 study (NCT04700124), molecular subtype analysis findings from NIAGARA, and ongoing bladder-preservation trials.

    Drs Park and Grivas also reviewed data in metastatic disease, including from cohort 7 of the phase 2 TROPHY-U-01 trial (NCT03547973), in which sacituzumab govitecan-hziy (Trodelvy) plus enfortumab vedotin and zimberelimab (AB122/GLS-010) yielded a high overall response rate. They also discussed data with sacituzumab tirumotecan (MK-2870/SKB264) plus pembrolizumab (Keytruda). In non–muscle-invasive disease, Dr Grivas discussed data from the phase 3 POTOMAC trial (NCT03528694) of durvalumab plus BCG and the role of shared decision-making in bladder cancer management. The experts concluded by highlighting developments in artificial intelligence, as well as the importance of patient advocacy and clinical trial participation.

    56 min
  • S19 Ep16: Thorough Treatment Adherence and Selection Anchor Proper TKI Utilization in CML
    In our exclusive interview, Dr Haddad discussed the importance of consistent daily adherence to oral TKIs for achieving deep responses, treatment-free remission, and long-term survival in patients with CML. Additionally, he broke down common barriers to TKI adherence, including busy schedules, travel, and under-recognized adverse effects (AEs), underscoring the use of dose reductions and therapy changes to manage AEs and keep patients on treatment. Finally, Haddad explored where liquid and orally disintegrating TKI formulations, such as imatinib oral solution (Imkeldi), may help patients who cannot swallow, those with advanced-phase CML or Philadelphia chromosome–positive acute lymphoblastic leukemia, and pediatric patients.
    10 min
  • S19 Ep15: How Allergists Fit Into the Systemic Mastocytosis Management Equation

    In today’s episode, we spoke with Nathan A. Boggs, MD, PhD, about the role the allergists play in the diagnosis and management of systemic mastocytosis. Dr Boggs is the director of the Allergy Division in the School of Medicine of Uniformed Services University of the Health Sciences in Bethesda, Maryland.

    In our exclusive interview, Dr Boggs broke down how allergists/immunologists fit into the multidisciplinary diagnosis and treatment of patients with systemic mastocytosis. Additionally, Boggs highlighted key strategies for symptom management and how agents such as avapritinib (Ayvakit), bezuclastinib (CGT9486), and elenestinib (BLU-263) have and will continue to affect the treatment paradigm.

    17 min
  • S19 Ep14: Board Review 2026: Top Hematology/Oncology Topics to Know

    Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

    In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a board exam preparation guide for the days leading up to the American Board of Internal Medicine hematology and oncology certification exams, offering test-day strategies and a rapid-fire review of high-yield topics.

    The discussion began with exam logistics, noting back-to-back testing days on November 17 (hematology) and November 18 (oncology). Drs Armstrong and Tawagi encouraged examinees to use the exam blueprint to prioritize high-yield topics, such as gastrointestinal, breast, genitourinary, and lung cancers in oncology and neoplasms in hematology, and to prepare for the endurance required to read lengthy clinical vignettes.

    Regarding oncology content, they reviewed topics to know regarding stage II and III non–small cell lung cancer, including staging, perioperative immunotherapy regimens, driver-directed adjuvant therapy, and the clinical implications of the phase 3 PACIFIC trial (NCT02125461). They then covered high-yield breast cancer topics, such as HER2-positive regimens, the 21-gene recurrence score assay cutoffs, triple-negative adjuvant strategies, and use of PARP inhibitors in patients with BRCA mutations.

    For hematology, they emphasized the malignant hematologic conditions, hemoglobin electrophoresis, von Willebrand disease subtypes, and inherited bone marrow failure syndromes, including dyskeratosis congenita, Fanconi anemia, and Diamond-Blackfan anemia.

    Drs Armstrong and Tawagi also highlighted other testable areas, including black box warnings, clinical research methodology, ethics, performance status–guided decision-making, and supportive care. They concluded with wellness advice, cautioning against last-minute cramming, and recommended revisiting their prior board review episodes.

    20 min
  • S19 Ep13: Beyond PD-L1: Refining First-Line Treatment Decisions in Metastatic NSCLC

    In this episode of OncLive On Air, Aditya Juloori, MD, a radiation oncologist and associate professor at the University of Chicago in Illinois, was joined by David Carbone, MD, PhD, a thoracic medical oncologist and director of the Thoracic Oncology Center at The Ohio State University in Columbus. Together, they explored how factors beyond PD-L1 expression, including histology, co-occurring genomic alterations, brain metastases, and patient fitness, can inform first-line regimen selection for patients with driver-negative metastatic non–small cell lung cancer (NSCLC).

    Dr Carbone began by explaining that immunotherapy has transformed the treatment landscape, with frontline regimens now producing an overall 5-year survival rate of approximately 20% and potentially curing a subset of patients. However, he noted that this benefit is not evenly distributed. Patients with PD-L1–negative disease tend to fare worse than those with PD-L1–positive tumors, and outcomes are particularly poor for patients with PD-L1–negative squamous disease. In the 5-year data from the phase 3 KEYNOTE-407 trial (NCT02775435), survival curves for this subgroup had fully converged with the control arm, and the 5-year survival rate among patients with PD-L1–negative nonsquamous disease in the phase 3 KEYNOTE-189 trial (NCT02578680) was below 10%.

    Drs Carbone and Juloori emphasized that dual checkpoint inhibition has emerged as an important option for these higher-risk populations. Dr Carbone highlighted that the CheckMate 9LA regimen (NCT03215706) of nivolumab (Opdivo) plus ipilimumab (Yervoy) with 2 cycles of chemotherapy produced a 5-year survival rate exceeding 20% in PD-L1–negative and squamous subsets, making it his preferred approach for patients with PD-L1–negative squamous disease. For PD-L1–negative nonsquamous tumors, he weighs additional factors such as brain metastases and STK11 or KEAP1 alterations. Although dual immunotherapy carries a higher risk of immune-related adverse effects, he noted that outcomes in CheckMate 9LA remained favorable even among patients who discontinued a component of therapy, underscoring the effectiveness of proactive toxicity management. He added that the chemotherapy-free regimen evaluated in the phase 3 CheckMate 227 trial (NCT02477826) demonstrated similar efficacy, and that many patients value receiving only 2 cycles of chemotherapy.

    The conversation also explored the management of patients with baseline brain metastases. Dr Juloori explained that in both CheckMate 227 and CheckMate 9LA, the benefit of dual immunotherapy was at least as large in patients with brain metastases as in those without. This may reflect the ability of CTLA-4 blockade to convert immunologically cold intracranial tumors, which tend to have fewer activated cytotoxic T cells and tertiary lymphoid structures, into more inflamed ones. He cited a phase 2 trial of ipilimumab, nivolumab, and chemotherapy that reported an intracranial response rate of approximately 50%. For patients with multiple asymptomatic brain metastases, Dr Juloori described starting the 9LA regimen with close monthly brain imaging to assess early intracranial response, an approach that can defer whole-brain radiation therapy and help preserve performance status and eligibility for subsequent therapies. He noted that some of his patients have avoided radiation for more than a year with sustained complete responses.

    Turning to genomic modifiers, Dr Carbone described STK11 and KEAP1 alterations as markers of immunologically cold, often PD-L1–negative tumors that may require more than standard chemotherapy plus pembrolizumab (Keytruda). The prospective phase 2 TRITON trial (NCT06008093) of durvalumab (Imfinzi) plus tremelimumab-actl (Imjudo) in STK11-, KEAP1-, or KRAS-mutant disease was limited by low accrual, but multiple studies support dual immunotherapy activity in these subsets. He cautioned, however, that mutation status is an imperfect surrogate for STK11 function, noting that his laboratory has identified mutant tumors that retain function and wild-type tumors that have lost it. As a result, he would still favor single-agent immunotherapy for a patient with high PD-L1 expression and an isolated STK11 mutation.

    Dr Carbone also addressed how to apply trial data to patients who are older, frail, or have reduced performance status. He suggested that limiting chemotherapy exposure may be particularly beneficial in these populations, while noting that patients with interstitial lung disease or active autoimmune conditions requiring aggressive immunosuppression may be poor candidates for dual immunotherapy. He added that age alone should not preclude more intensive treatment in patients with good performance status and organ function. Both experts expressed a preference for nivolumab plus ipilimumab over durvalumab plus tremelimumab, citing stronger supporting data, particularly in squamous disease.

    Looking ahead, Dr Carbone noted that emerging tools, including serum proteomic assays and SMARCA4 status, may eventually be incorporated into treatment algorithms, though their role in the dual immunotherapy and PD-L1–negative settings remains undefined. Drs Carbone and Juloori concluded that while clinicians often must rely on incomplete data and cross-trial comparisons, decisions should remain grounded in the available evidence as the field works toward more precise tools for moving beyond PD-L1.

    22 min
  • S19 Ep12: Order Both IHC and NGS: Defining MET Alterations and Positioning Telisotuzumab Vedotin in Non–Small Cell Lung Cancer

    In today’s episode, we spoke with Lyudmila Bazhenova, MD, and Sandip Patel, MD. Dr Bazhenova is a thoracic medical oncologist and co-lead of the lung cancer team at University of California San Diego Moores Cancer Center, and Dr Patel is a professor of medical oncology at UC San Diego.

    In our exclusive interview, Drs Bazhenova and Patel explained why describing a tumor as “MET positive” is no longer specific enough in non–small cell lung cancer (NSCLC). MET protein overexpression, MET exon 14 skipping mutations, and MET amplification are biologically distinct findings detected by different assays, and each carries its own treatment implications. Protein overexpression is identified by immunohistochemistry (IHC) on tumor tissue and defines eligibility for the antibody-drug conjugate (ADC) telisotuzumab vedotin-tllv (Emrelis), which is approved for the treatment of adult patients with locally advanced or metastatic, nonsquamous NSCLC harboring high c-MET protein overexpression who have received a prior systemic therapy; c-MET protein overexpression is defined as at least 3+ staining in 50% or more of tumor cells per IHC testing. Dr Patel noted that roughly 1 in 5 patients may harbor this target. MET exon 14 skipping mutations, found in approximately 2% to 4% of patients, are genomic alterations detectable by next-generation sequencing (NGS) on tissue or liquid biopsy and are treated with the MET inhibitors capmatinib (Tabrecta) or tepotinib (Tepmetko). Dr Bazhenova cautioned that DNA-based NGS can miss MET exon 14 skipping mutations, making RNA-based testing a valuable complement. MET amplification, which can arise de novo or as a resistance mechanism after third-generation EGFR inhibition, lacks a specific FDA-approved therapy, although Dr Patel described combining an EGFR inhibitor such as osimertinib (Tagrisso) with a MET inhibitor in the acquired-resistance setting.

    Because IHC and NGS measure different things, both experts order the 2 tests together rather than treating one as a substitute for the other. Dr Bazhenova likened NGS to examining a home’s blueprint and IHC to inspecting what was actually built, adding that high protein expression without a corresponding genomic alteration is not a discordant result. Dr Patel described sending liquid biopsy for genomic profiling alongside tissue so that limited tissue can be preserved for PD-L1, HER2, and MET IHC. When tissue is insufficient, he obtains a biopsy before second-line therapy, and he stressed documenting the exact aberration and score in the medical record so the finding can guide treatment years later. Dr Bazhenova also routinely repeats NGS and IHC at progression on EGFR-targeted therapy, since MET alterations are a common escape mechanism and acquired MET overexpression can emerge.

    The experts also addressed borderline IHC results and assay variability. Dr Patel noted that interpretation tends to be more consistent at high-intensity, high-percentage staining with the SP44 assay, and he encouraged direct conversations with pathologists and multidisciplinary tumor boards for cases near the cutoff. Dr Bazhenova highlighted data from the phase 2 LUMINOSITY trial (NCT03539536) showing activity in MET-intermediate tumors, defined as IHC 3+ staining in 25% to 50% of cells, with an overall response rate of 23% and a median duration of response of about 7 months, although this population falls outside the current label. She pointed to the ongoing phase 3 TeliMET NSCLC-01 trial (NCT04928846) comparing telisotuzumab vedotin with docetaxel in both MET-high and -intermediate disease, and recommended considering a repeat biopsy for patients near the threshold given tumor heterogeneity.

    On sequencing, Dr Patel described telisotuzumab vedotin as his standard of care for eligible patients after chemoimmunotherapy, citing a more favorable efficacy and toxicity profile than docetaxel, which yields a response rate of roughly 9%. He added that giving docetaxel first may blunt the benefit of a subsequent ADC with a similar mechanism. For patients with EGFR-mutant disease and acquired MET overexpression, Dr Bazhenova said she would favor datopotamab deruxtecan-dlnk (Datroway), noting that telisotuzumab vedotin produced a response rate of only about 16% in this group in LUMINOSITY. Looking ahead, she flagged payload-aware sequencing as a growing challenge, because many ADCs in development share a topoisomerase I inhibitor payload and trials often exclude patients previously exposed to that payload class, leaving little data to guide back-to-back use.

    26 min

About OncLive® On Air

From the publisher's feed

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in…

Best of OncLive® On Air

Ranked by our users in the last 21 days

More shows like OncLive® On Air

Left, Right & Center by KCRW

Left, Right & Center

5,123 Listeners

The Ben Shapiro Show by The Daily Wire

The Ben Shapiro Show

153,157 Listeners

NEJM This Week by NEJM Group

NEJM This Week

322 Listeners

Nature Podcast by Springer Nature Limited

Nature Podcast

769 Listeners

Research To Practice | Oncology Videos by Dr Neil Love

Research To Practice | Oncology Videos

121 Listeners

ASCO Daily News by American Society of Clinical Oncology (ASCO)

ASCO Daily News

56 Listeners

Audio Journal of Oncology Podcast by Audio Medica News

Audio Journal of Oncology Podcast

0 Listeners

OncoPharm by John Bossaer

OncoPharm

187 Listeners

ASCO Guidelines by American Society of Clinical Oncology (ASCO)

ASCO Guidelines

46 Listeners

The Uromigos by The Uromigos

The Uromigos

59 Listeners

Simple English News Daily by SEND7

Simple English News Daily

29 Listeners

Oncology Today with Dr Neil Love by Dr. Neil Love

Oncology Today with Dr Neil Love

58 Listeners

People I (Mostly) Admire by Freakonomics Radio + Stitcher

People I (Mostly) Admire

1,987 Listeners

Oncology Brothers: Practice-Changing Cancer Discussions by Oncology Brothers

Oncology Brothers: Practice-Changing Cancer Discussions

46 Listeners

English Learning Podcast by EnglishPod

English Learning Podcast

33 Listeners